Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

49 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Zoledronic acid slows down rat primary chondrosarcoma development, recurrent tumor progression after intralesional curretage and increases overall survival.
Gouin F, Ory B, Rédini F, Heymann D. Gouin F, et al. Among authors: ory b. Int J Cancer. 2006 Sep 1;119(5):980-4. doi: 10.1002/ijc.21951. Int J Cancer. 2006. PMID: 16570273
Bisphosphonates: new therapeutic agents for the treatment of bone tumors.
Heymann D, Ory B, Gouin F, Green JR, Rédini F. Heymann D, et al. Among authors: ory b. Trends Mol Med. 2004 Jul;10(7):337-43. doi: 10.1016/j.molmed.2004.05.007. Trends Mol Med. 2004. PMID: 15242682 Review.
Enhanced tumor regression and tissue repair when zoledronic acid is combined with ifosfamide in rat osteosarcoma.
Heymann D, Ory B, Blanchard F, Heymann MF, Coipeau P, Charrier C, Couillaud S, Thiery JP, Gouin F, Redini F. Heymann D, et al. Among authors: ory b. Bone. 2005 Jul;37(1):74-86. doi: 10.1016/j.bone.2005.02.020. Bone. 2005. PMID: 15894525
Zoledronic acid suppresses lung metastases and prolongs overall survival of osteosarcoma-bearing mice.
Ory B, Heymann MF, Kamijo A, Gouin F, Heymann D, Redini F. Ory B, et al. Cancer. 2005 Dec 1;104(11):2522-9. doi: 10.1002/cncr.21530. Cancer. 2005. PMID: 16270320
Zoledronic acid activates the DNA S-phase checkpoint and induces osteosarcoma cell death characterized by apoptosis-inducing factor and endonuclease-G translocation independently of p53 and retinoblastoma status.
Ory B, Blanchard F, Battaglia S, Gouin F, Rédini F, Heymann D. Ory B, et al. Mol Pharmacol. 2007 Jan;71(1):333-43. doi: 10.1124/mol.106.028837. Epub 2006 Oct 18. Mol Pharmacol. 2007. PMID: 17050806
mTOR inhibitors (rapamycin and its derivatives) and nitrogen containing bisphosphonates: bi-functional compounds for the treatment of bone tumours.
Ory B, Moriceau G, Redini F, Heymann D. Ory B, et al. Curr Med Chem. 2007;14(13):1381-7. doi: 10.2174/092986707780831159. Curr Med Chem. 2007. PMID: 17584050 Review.
Relevance of a new rat model of osteoblastic metastases from prostate carcinoma for preclinical studies using zoledronic acid.
Lamoureux F, Ory B, Battaglia S, Pilet P, Heymann MF, Gouin F, Duteille F, Heymann D, Redini F. Lamoureux F, et al. Among authors: ory b. Int J Cancer. 2008 Feb 15;122(4):751-60. doi: 10.1002/ijc.23187. Int J Cancer. 2008. PMID: 17960623
Farnesyl diphosphate synthase is involved in the resistance to zoledronic acid of osteosarcoma cells.
Ory B, Moriceau G, Trichet V, Blanchard F, Berreur M, Rédini F, Rogers M, Heymann D. Ory B, et al. J Cell Mol Med. 2008 Jun;12(3):928-41. doi: 10.1111/j.1582-4934.2008.00141.x. J Cell Mol Med. 2008. PMID: 18494934 Free PMC article.
Therapeutic approach of primary bone tumours by bisphosphonates.
Moriceau G, Ory B, Gobin B, Verrecchia F, Gouin F, Blanchard F, Redini F, Heymann D. Moriceau G, et al. Among authors: ory b. Curr Pharm Des. 2010;16(27):2981-7. doi: 10.2174/138161210793563554. Curr Pharm Des. 2010. PMID: 20722622 Review.
Zoledronic acid potentiates mTOR inhibition and abolishes the resistance of osteosarcoma cells to RAD001 (Everolimus): pivotal role of the prenylation process.
Moriceau G, Ory B, Mitrofan L, Riganti C, Blanchard F, Brion R, Charrier C, Battaglia S, Pilet P, Denis MG, Shultz LD, Mönkkönen J, Rédini F, Heymann D. Moriceau G, et al. Among authors: ory b. Cancer Res. 2010 Dec 15;70(24):10329-39. doi: 10.1158/0008-5472.CAN-10-0578. Epub 2010 Oct 22. Cancer Res. 2010. PMID: 20971812 Free PMC article.
49 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page